author-photo

Sacha I. Rothschild

University Hospital of Basel

14

Papers

67

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

Safety and efficacy of perioperative cisplatin/gemcitabine (cis/gem) and durvalumab (durva) for operable muscle-invasive urothelial carcinoma (MIUC): SAKK 06/17.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small Cell Lung Cancer — A Multicentre Single-Arm Phase II Trial

2021 Social Science Research Network
Show All
- Source
- Cite
- Save
Citations (0)
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (15)
P30.01 Extended Resections for Advanced Stages T3/T4 NSCLC After Neoadjuvant Treatment: Conclusions of SAKK Pooled Analysis (16/96, 16/00, 16/01)

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Tumour neoantigen mimicry by microbial species in cancer immunotherapy.

2021 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (20)
Second-line therapy to improve overall survival in primary refractory non small-cell lung cancer (NSCLC) patients.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Tumor mutational burden assessed by a targeted NGS assay to predict benefit from immune checkpoint inhibitors in non-small cell lung cancer.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)